Results 181 to 190 of about 43,362 (258)

Association between visual hallucinations and α-synuclein oligomers in patients with dementia with Lewy bodies. [PDF]

open access: yesAlzheimers Dement
Sekiya H   +10 more
europepmc   +1 more source

A Systematic Comparison of Alpha‐Synuclein Seed Amplification Assays for Increasing Reproducibility

open access: yesAnnals of Clinical and Translational Neurology, Volume 13, Issue 6, Page 1088-1105, June 2026.
ABSTRACT Seed amplification assays (SAAs) enable ultrasensitive detection of misfolded α‐synuclein across biofluids and tissues. Yet, heterogeneity in protocols limits cross‐study comparability and clinical translation. Here, we review α‐synuclein SAA methods and their performance across various biological matrices.
Manuela Amaral‐do‐Nascimento   +3 more
wiley   +1 more source

Lysosome‐Acidifying Nanoparticles Rescue A30P α‐Synuclein Induced Neuronal Death in Cellular and Drosophila Models of Parkinson's Disease

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 22, 12 June 2026.
Lysosome‐targeted acidic nanoparticles based on a biodegradable poly(ethylene tetrafluorosuccinate‐co‐succinate) copolymer are engineered to restore impaired lysosomal acidification through pH‐responsive intracellular degradation. Localized acid release enhances autophagic proteolysis, reduces α‐synuclein accumulation, and preserves dopaminergic neuron
Chih Hung Lo   +6 more
wiley   +1 more source

Small Extracellular Vesicles from Neural Cells: Physiological and Pathological Roles, and Potential in Neurodegenerative Therapy

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 21, 5 June 2026.
Neural cell–derived small extracellular vesicles (sEVs) are emerging as pivotal mediators in neurodegenerative diseases, exerting both pathogenic and therapeutic functions. This review synthesizes current evidence on how sEVs from distinct neural cell types regulate neurodegeneration, neuroprotection, biomarker discovery, and targeted drug delivery ...
Muhammad Waqas Salim   +4 more
wiley   +1 more source

Cognitive Trajectories from Preclinical Alzheimer's Disease to Dementia

open access: yesAdvanced Science, Volume 13, Issue 32, 9 June 2026.
A continuous, multi‐domain characterization of cognitive decline across the Alzheimer's disease spectrum identifies when individual cognitive measures become abnormal. Episodic memory declines first, followed by executive function, language, processing speed, and visuospatial abilities, supporting improved clinical interpretation and optimized endpoint
Fredrik Öhman   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy